DOCSLIB.ORG

Antidepressive Effect of Nicergoline on Patients with Mild Post-Stroke Depression

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Antidepressive Effect of Nicergoline on Patients with Mild Post-Stroke Depression ● Original Antidepressive Effect of Nicergoline on Patients with Mild Post-stroke Depression Yasuhiro Nishiyama1）, Yuichi Komaba1） Sunao Mizumura2） and Yasuo Katayama1） Abstract Background and Purpose : Post-stroke depression（PSD）is considered the most frequent and important neu- ropsychiatric complication in stroke patients. Antidepressants are commonly used in the treatment of severe PSD, but these drugs are not necessarily administered to patients with mild PSD. Nicergoline is an ergoloid mesylate derivative currently used for the treatment of cognitive and behavioral disorders of older people or neuropsychological impairments in cerebrovascular disorders, though antidepressive effects of nicergoline is unknown. We investigated whether nicergoline is effective on patients with mild PSD instead of antidepres- sants. Methods : We selected 6 patients with mild PSD defined by the Zung’s self-rating depression scale（SDS）1 month after the onset of stroke. Nicergoline（15 mg!day）was administered for four weeks to the patients one month after the onset of cerebral infarction. Depression was also evaluated using SDS after administration of nicergoline. Furthermore, we evaluated the effect of nicergoline on three subscales of SDS, i.e., cognitive, affec- tive and somatic symptoms. Results : The SDS score improved significantly in all patients after treatment（p＝0.0042）. The analysis of three subscales revealed that the cognitive symptom in the SDS scores is a significant improved（p＝0.026）. Conclusions : Our findings suggest that niceijoke nicergoline has antidepressive effect on patients with mild PSD instead of antidepressants and diagnosis of PSD should be performed in early period of stroke. （Cerebral Blood Flow and Metabolism 17 : 11―16, 2005） Key words : nicergoline, depression, cerebrovascular disease adverse impact on functional recovery2） and sur- Introduction vival3）. It has previously been reported that PSD is an independent predictor of poor long-term func- Symptoms of depression, such as deteriorated mo- tional outcome4,5）. Recent reports underlined the im- tivation and apathy, after stroke are collectively portance of early treatment for PSD that can have a called poststroke depression（PSD）, and the concept positive effect on rehabilitation and functional recov- of PSD has been established in recent years. Post- ery of the patients6,7）. stroke depression（PSD）is considered as the most Nicergoline is an ergoloid mesylate derivative with frequent and important neuropsychiatric complica- pharmacological actions such as cerebral metabo- tion in stroke patients, since 12％ to 64％ of stroke lism-improving action8） and cerebral neurotransmi- survivors experience depression both early and late ssion-improving action9）. Nicergoline is also effective after stroke1） and since this condition can have an from the clinical view point in improving decreased motivation and initiative10）. However, effect of nicer- 1）The Second Department of Internal Medicine, 2）Depart- goline for PSD is unclear. In the treatment of PSD, ment of the Radiology, Nippon Medical School tricyclic, tetracyclic antidepressants, or selective ―11― 脳循環代謝 第 17 巻 第 1 号 Table 1. Background SDS 1 Age Diagnosis Atrial Case Sex month after Hypertension Hyperlipidemia Diabetes Smoking （yr） （lesion location） fibrillation onset 1 81 F Atherothrombotic infarction 52 ＋ ＋ － － － （left putamen to radio corporis callosi） 2 76 M Atherothrombotic infarction 51 ＋ － － － ＋ （left arteria cerebri media area） 3 55 M Atherothrombotic infarction 46 － － － － ＋ （left pons） 4 68 M Cardiogenic cerebral embolism 46 － － － ＋ ＋ （left arteria cerebri anterior area） 5 67 M Lacunar infarction 44 ＋ － ＋ － － （left medulla oblongata） 6 77 F Cardiogenic cerebral embolism 41 ＋ － － ＋ － （right arteria cerebri posterior area） serotonin reuptake inhibitors（SSRI）is commonly ad- ministered, but cannot be administered to some pa- tients, especially elderly patients, because of their side effects. As a result, these antidepressants are not often administerd to patients with mild PSD. Here we investigate whether nicergoline has antide- presseive effect on mild PSD. Subjects and Methods Fig. 1. Changes in Zung self-rating depression scale The present study included 30 of 36 consecutive （SDS）scores after treatment with nicergoline. All pa- patients with their first significant acute-ischemic tients treated with nicergoline had significantly better stroke admitted to the Department of Neurology, scores after treatment with nicergoline（p＝0.0042 ; paired t-test）. The scores changed from 47.17±4.26 to Nippon Medical School between June and Septem- 40.33±4.96. There was a significant reduction of the ber 2002. Diagnosis of stroke was made clinically by scores after treatment with nicergoline. stroke with experienced stroke neurologists using the Trial of ORG 10172 in Acute Stroke Treatrment （TOAST）criteria11）. All patients was underwent CT Of these patients, 4 were male, and 2 were female ; and!or MRI scanning. We selected the 30 patients their mean age±SD was 70.6±9.4 years（range, 55 who met the following criteria（I）no : severe apha- to 81）. The patients’clinical backgrounds data are sia（II）no ; reduced level of consciousness（III）no ; summarized in Table 1. One tablet（5 mg）of nicer- dementia（IV）no ; alcohol abuse（V）no ; psychosis goline was administered three times daily for four or current antidepressant treatment. Six of 36 pa- consecutive weeks. PSD was also evaluated by SDS tients were excluded. All 30 patients were evaluated after the administration of nicergoline. The 20 items using the Zung SDS12） one month after the onset. of SDS were divided into the following three The 20 items of SDS are scored according to a stan- subscales according to the report of Sakamoto et dard 4-point scale（1 to 4）for each item, with a poten- al14）. 1）cognitive symptoms, 2）affective symptoms, tial range of 20 to 80. Mild PSD was defined be- and 3）somatic symptoms. SDS item Nos. 11, 12, 14, tween 40 and 59 points according to the the report 16, 17, 18, and 20, Nos. 1, 3, 10, 13, and 15, and Nos. 4, of Herrmann2） and Ohira13）. From among patients, six 5, 7, and 9 were considered to represent cognitive, patients were remained, meeting mild PSD criteria. affective and somatic symptoms, respectively. Cere- All six patients were administerd with nicergoline. bral blood flow was also quantified in one patient be- ―12― Nicergoline for Depression after Stroke Fig. 2. Changes in three subscales of SDS after treatment with nicergoline. After treatment with nicergoline, cognitive symptoms were significantly improved（p＝ 0.026 ; paired t-test）. However, no statistically significant differences were found regarding affective symptoms（p＝0.091 ; paired t-test）or somatic symptoms（p＝ 0.095 ; paired t-test）. Fig. 3. Cerebral blood flow and images obtained by single photon emission com- puted tomography（SPECT）with N-idopropil-p-［123I］-iodoamphetamine（123I-IMP） before and after treatment with nicergoline in Case 1. A. Cerebral blood flow was quantified before and after treatment with nicergoline in relation to the location of the lesions. B . Imaging of cerebral blood flow by SPECT before and after treat- ment．（before : before nicergoline treatment ; after : after nicergoline treatment） Little increases of the cerebral blood flow in the occipital cortex and in the thala- mus on the left side, as well as approximately 10％ increases in the bilateral striata were noticed, but no other clear changes were observed. ―13― 脳循環代謝 第 17 巻 第 1 号 fore and after nicergoline treatment using on recovery of functions, some authors4,5） have con- N-idopropil-p-［123I］-iodoamphetamine（123I-IMP）single firmed that PSD is an independent predictor of poor photon emission computed tomography（SPECT）. long-term functional outcome. The influence of PSD The location of the lesion detected by SPECT was on post-stroke outcome has been confirmed by a re- as follows : frontal lobe, temporal lobe, parietal lobe, cent study18）, which has shown that the presence of occipital lobe, white matter, striatum, thalamus, PSD 1 month after stroke increases the risk of mor- brainstem and cerebellum, as previously reported15,16）. tality 12 and 24 months later. Gonzalez-Torrecillas et Changes in SDS scores after nicergoline administra- al6） and, recently Miyai and Reding7） and Chemerin- tion were statistically assessed using a paired t-test. ski et al.19） underlined the importance of early treat- ment for PSD that can have a positive effect on the Results outcome of the patients. Depression itself is responsi- ble for the delay in rehabilitation and the prevention As illustrated in Figure 1, SDS scores after treat- of functional recovery. Therefore, diagnosis of PSD ment with nicergoline were significantly improved in should be performed in early period of stroke. all the patients（p＝0.0042 ; paired t-test）.Theim- Moreover, we divided the 20 items of SDS into provement shown by the three subscales was statis- three subscales, that is cognitive, affective and so- tically analyzed. As shown in Figure 2, cognitive matic symptoms, and then compared the scores of symptoms showed a significant improvement after these subscales obtained before and after treatment treatment（p＝0.026 ; paired t-test）. No statistically with nicergoline. Our results revealed a significantly significant differences were found regarding affec- better improvement of cognitive symptoms, while tive symptoms（p＝0.091 ; paired t-test）or somatic there was no significant improvement in affective or symptoms（p＝0.095 ; paired t-test）. Cerebral blood somatic symptoms. In a previous study, nicergoline flow in Case 1 is shown in Figure 3. Apart from a lit- was found to inhibit the activity of brain acetyl- tle increases of the cerebral blood flow in the occipi- cholineesteraseinmiceandrats20）. The central tal cortex and the thalamus on the left side and ap- cholinergic system is known to play a fundamental proximately 10％ increases of blood flow in the bilat- role in cognitive function, and extensive evidence in- eral striae, no other noticeable changes were ob- dicates that a disruption of the cholinergic function served. leads to characterisic signs of aging and Alzheimer’s disease.
Load more

Recommended publications
  • Inline-Supplementary-Material-1.Pdf
    Appendix 1: STOPP/START criteria version 2 applied to the TRUST dataset Physiological system Criteria Criteria included Number (%) (The relevant () criteria for each participant were applied to the dataset and recorded in of Microsoft Office Excel ® (2013)) criteria included out of total criteria STOPP criteria Indication of medication A1. Any drug prescribed without an evidence-based clinical indication. X 1/3 (33.3) A2. Any drug prescribed beyond the recommended duration, where treatment duration is X well defined. A3. Any duplicate drug class prescription e.g. two concurrent NSAIDs, SSRIs, loop diuretics, ACE inhibitors, anticoagulants (optimisation of monotherapy within a single drug class should be observed prior to considering a new agent). Cardiovascular system B1. Digoxin for heart failure with preserved systolic ventricular function (no clear evidence X 7/13 (53.8) of benefit). B2. Verapamil or diltiazem with NYHA Class III or IV heart failure (may worsen heart failure). B3. Beta-blocker in combination with verapamil or diltiazem (risk of heart block). B4. Beta blocker with symptomatic bradycardia (< 50/min), type II heart block or complete heart block (risk of profound hypotension, asystole). B5. Amiodarone as first-line antiarrhythmic therapy in supraventricular tachyarrhythmias X (higher risk of side-effects than beta-blockers, digoxin, verapamil or diltiazem). B6. Loop diuretic as first-line treatment for hypertension (safer, more effective alternatives available). B7. Loop diuretic for dependent ankle oedema without clinical, biochemical evidence or radiological evidence of heart failure, liver failure, nephrotic syndrome or renal failure (leg elevation and /or compression hosiery usually more appropriate). B8. Thiazide diuretic with current significant hypokalaemia (i.e.
    [Show full text]
  • PDF Download
    CURRENT THERAPEUTIC RESEARCH VOL. 56, NO. 5, MAY 1995 EFFECTS OF CEREBRAL METABOLIC ENHANCERS ON BRAIN FUNCTION IN RODENTS KOICHIRO TAKAHASHI,l MINORU YAMAMOTO,’ MASANORI SUZUKI,’ YUKIKO OZAWA,’ TAKASHI YAMAGUCHI,l HIROFUMI ANDOH, AND KOUICHI ISHIKAWA2 ‘Department of Pharmacology, Clinical Pharmacology Research Laboratory, Yamunouchi Pharmaceutical Co. Ltd., and ‘Department of Pharmacology, School of Medicine, Nihon University, Tokyo, Japan AFWI’RACT The effects of cerebral metabolic enhancers (indeloxazine, bi- femelane, idebenone, and nicergoline) on reserpine-induced hypother- mia, the immobility period in forced swimming tests, and passive avoidance learning behavior were compared with the effects of ami- triptyline in rodents. Indeloxazine, bifemelane, and amitriptyline antagonized hypothermia in mice given reserpine. Indeloxaxine and amitriptyline decreased the immobility period in mice in the forced swimming test in a dose-dependent manner. The latency of step- through in the passive avoidance test in rats was prolonged by ad- ministration of indeloxazine but shortened by administration of amitriptyline. Neither idebenone nor nicergoline displayed any phar- macologic action in these tests. The results suggest that indeloxaxine possesses an antidepressant activity similar to that of amitriptyline but differs from amitriptyline in its anticholinergic properties and its ability to ameliorate impaired brain function such as that of learning behavior. In addition, indeloxazine exhibited broader effects on brain functions than either bifemelane, idebenone, or nicergoline. INTRODUCTION Cerebral metabolic enhancers (drugs that enhance energy metabolism) including brain glucose and ATP levels such as indeloxazine,1*2 bi- femelane, 3*4idebenone?6 and nicergoline,7>8 are currently used for the treatment of patients with various psychiatric symptoms. These symptoms include reduced spontaneity and emotional disturbance in patients with cerebral vascular disease.
    [Show full text]
  • Local Product Document Pfizer Venezuela, S.A
    LOCAL PRODUCT DOCUMENT PFIZER VENEZUELA, S.A. 1. MEDICINAL PRODUCT BRAND NAME ® SERMION 2. CUALITATIVE AND CUANTITATIVE COMPOSITION Every coated tablet contains 10 and 30 mg of Nicergoline. 3. PHARMACEUTICAL FORM Coated tablets. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS 1. Cerebrovascular insufficiency of senile source. 2. Peripheral Vasodilator. 3. Treatment of Senile dementia from light to medium level of vascular type and Alzheimer. 4.2 DOSAGE 1. 30 mg/day and Cerebrovascular insufficiency of senile source. 2. 30 mg twice per day, as Peripheral Vasodilator and on treatment of Senile dementia from light to medium level of vascular type and Alzheimer. 4.3 CONTRAINDICATIONS Hypersensitivity to Nicergoline. 4.4 WARNINGS AND PRECAUTIONS Nicergoline, as other adrenergic blocking agents, may significantly reduce blood pressure (arterial hypotension) in some patients. Likewise, as other sympatholytic agents, it has been associated to different degrees of sexual impotence and libido reduction. Do not administer this product if pregnant, if pregnancy is suspected or during breast-feeding. 4.5 ADVERSE EFFECTS Drowsiness, cephalea, tiredness, constipation, pyrosis, vomiting, diarrhea, facial flushing, sexual impotence and libido reduction, uric acid and L.H increment. 5. PHARMACOLOGICAL PROPERTIES 5.1 Pharmacokinetics Properties A) Onset and Duration - Benign prostatic hypertrophy, intramuscular: 2 hours. - Two hours after a single 4-mg intramuscular injection, average peak and mean urinary flow rates increased by 50% and 77%, respectively. B) Drug Concentration Levels - ORAL: 1 to 1.5 hours. - Maximal blood levels are reached 1 to 1.5 hours after oral dosing. - The mean maximum plasma concentrations after daily administration of a 30-mg film-coated tablet and a 30-mg effervescent tablet solution are 88 ng/mL and 41 ng/mL, respectively).
    [Show full text]
  • Non-Antibiotics, Efflux Pumps and Drug Resistance of Gram-Negative Rods
    Polish Journal of Microbiology MINIREVIEW 2018, Vol. 67, No 2, 129–135 DOI: 10.21307/pjm-2018-017 Non-antibiotics, Efflux Pumps and Drug Resistance of Gram-negative Rods AGNIESZKA EWA LAUDY* Department of Pharmaceutical Microbiology, Medical University of Warsaw, Warsaw, Poland Submitted 24 March 2018, revised 29 March 2018, accepted 04 April 2018 Abstract Non-antibiotic medicinal products consist of drugs with diverse activity against bacteria. Many non-antibiotics demonstrate direct anti- bacterial activity against Gram-positive cocci. The activity observed against Gram-negative rods is much lower and non-antibiotics primarily from the following groups: non-steroidal anti-inflammatory drugs, cardiovascular and antidepressant medicinal products demonstrate this activity. It has been shown that the low activity of some non-antibiotics or the absence of activity against Gram-negative rods is related, among other things, to the extrusion of these compounds from bacterial cells by multi-drug resistance efflux pumps. Substrates for the resistance-nodulation-division efflux systems include the following non-antibiotics: salicylate, diclofenac, ibuprofen, mefenamic acid, naproxen, amitriptyline, alendronate sodium, nicergoline, and ticlopidine. In addition, interactions between non-antibiotics and multi-drug resistance efflux pumps have been observed. It has also been revealed that depending on the concentration, salicylate induces expression of multi-drug resistance efflux pumps in Escherichia coli, Salmonella enterica subsp. enterica serotype Typhimurium, and Burkholderia cenoce­ pacia. However, salicylate does not affect the expression of the resistance-nodulation-division efflux systems Stenotrophomonasin maltophilia and Acinetobacter baumannii. Most importantly, there were no effects of medicinal products containing some non-antibiotic active substances, except salicylate, as substrates of multi-drug resistance efflux pumps, on the induction of Gram-negative rod resistance to quinolones.
    [Show full text]
  • 4 Supplementary File
    Supplemental Material for High-throughput screening discovers anti-fibrotic properties of Haloperidol by hindering myofibroblast activation Michael Rehman1, Simone Vodret1, Luca Braga2, Corrado Guarnaccia3, Fulvio Celsi4, Giulia Rossetti5, Valentina Martinelli2, Tiziana Battini1, Carlin Long2, Kristina Vukusic1, Tea Kocijan1, Chiara Collesi2,6, Nadja Ring1, Natasa Skoko3, Mauro Giacca2,6, Giannino Del Sal7,8, Marco Confalonieri6, Marcello Raspa9, Alessandro Marcello10, Michael P. Myers11, Sergio Crovella3, Paolo Carloni5, Serena Zacchigna1,6 1Cardiovascular Biology, 2Molecular Medicine, 3Biotechnology Development, 10Molecular Virology, and 11Protein Networks Laboratories, International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, 34149, Trieste, Italy 4Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy 5Computational Biomedicine Section, Institute of Advanced Simulation IAS-5 and Institute of Neuroscience and Medicine INM-9, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany 6Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, Italy 7National Laboratory CIB, Area Science Park Padriciano, Trieste, 34149, Italy 8Department of Life Sciences, University of Trieste, Trieste, 34127, Italy 9Consiglio Nazionale delle Ricerche (IBCN), CNR-Campus International Development (EMMA- INFRAFRONTIER-IMPC), Rome, Italy This PDF file includes: Supplementary Methods Supplementary References Supplementary Figures with legends 1 – 18 Supplementary Tables with legends 1 – 5 Supplementary Movie legends 1, 2 Supplementary Methods Cell culture Primary murine fibroblasts were isolated from skin, lung, kidney and hearts of adult CD1, C57BL/6 or aSMA-RFP/COLL-EGFP mice (1) by mechanical and enzymatic tissue digestion. Briefly, tissue was chopped in small chunks that were digested using a mixture of enzymes (Miltenyi Biotec, 130- 098-305) for 1 hour at 37°C with mechanical dissociation followed by filtration through a 70 µm cell strainer and centrifugation.
    [Show full text]
  • Safety of Nicergoline As an Agent for Management of Cognitive Function Disorders
    Hindawi Publishing Corporation BioMed Research International Volume 2014, Article ID 610103, 6 pages http://dx.doi.org/10.1155/2014/610103 Review Article Safety of Nicergoline as an Agent for Management of Cognitive Function Disorders Bernd Saletu, Amit Garg, and Ahsan Shoeb Section of Sleep Research and Pharmacopsychiatry, Department of Psychiatry, Medical University of Vienna, Waehringer Guertel, 1090 Vienna, Austria Correspondence should be addressed to Amit Garg; [email protected] Received 13 March 2014; Revised 4 August 2014; Accepted 12 August 2014; Published 28 August 2014 Academic Editor: Rui Liu Copyright © 2014 Bernd Saletu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Nicergoline is a semisynthetic ergot derivative and has a selective alpha-1A adrenergic receptor blocking property and also other additional mechanisms of actions, both in the brain and in the periphery. It is in clinical use for over three decades in over fifty countries for conditions such as cerebral infarction, acute and chronic peripheral circulation disorders, vascular dementia, and Alzheimer’s disease and has been found to be beneficial in a variety of other conditions. However, concerns about its safety have been raised, especially after the European medicines agency’s (EMEA’s) restriction in the use of all ergot derivatives including nicergoline. But, most of the available literature and data suggest that the adverse events with nicergoline are mild and transient. Further, none of the available treatment options for cognitive disorders afford definitive resolution of symptoms.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Ergot Derivatives Art. 31
    27 September 2013 EMA/750632/2013 Assessment report Ergot derivatives containing medicinal products International Non-proprietary Name: nicergoline Procedure number: EMEA/H/A-31/1325 Referral under Article 31 of Directive 2001/83/EC Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8416 E -mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2014. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 3 1.1. Referral of the matter to the CHMP ......................................................................... 3 2. Scientific discussion ................................................................................ 3 2.1. Introduction......................................................................................................... 3 2.2. Clinical efficacy .................................................................................................... 4 2.2.1. Results ............................................................................................................. 4 2.2.2. Discussion ........................................................................................................ 9 2.3. Clinical safety ...................................................................................................
    [Show full text]
  • A7471055 Treatment Access Protocol For
    Dacomitinib A7471055 Protocol, 28 January 2015 CLINICAL PROTOCOL — A7471055 TREATMENT ACCESS PROTOCOL FOR PATIENTS PREVIOUSLY TREATED WITH DACOMITINIB ON A CLINICAL TRIAL IN JAPAN Compound: PF-00299804 Compound Name: Dacomitinib United States (US) Investigational New CCI Drug (IND) Number: European Clinical Trials Database N/A (EudraCT) Number: Protocol Number: A7471055 Phase: Phase 2 Page 1 Dacomitinib A7471055 Protocol, 28 January 2015 Document History Document Version Date Summary of Changes Original Protocol 28 January 2015 Not Applicable (N/A) Page 2 Dacomitinib A7471055 Protocol, 28 January 2015 Abbreviations Abbreviation Term AE adverse event ALT alanine transaminase AST aspartate transaminase ATP adenosine triphosphate BUN blood urea nitrogen CRF case report form CSA clinical study agreement CSR clinical study report CTCAE Common Terminology Criteria for Adverse Events DAI dosage and administration instructions DMC data monitoring committee DVT deep vein thrombosis EC ethics committee ECG Electrocardiogram ECOG Eastern Cooperative Group EDP exposure during pregnancy EGFR epidermal growth factor receptor EDTA edetic acid (ethylenediaminetetraacetic acid) GCP Good Clinical Practice HDPE High Density PolyEthylene HER Human Epidermal Growth Factor receptor IB Investigator’s Brochure ICH International Conference on Harmonisation ID Identification IEC institutional ethics committee IND investigational new drug application INR international normalized ratio IRB institutional review board IUD intrauterine device KRAS Kirsten Rat Sarcoma
    [Show full text]
  • Ergot Alkaloids: a Review on Therapeutic Applications
    European Journal of Medicinal Plants 14(3): 1-17, 2016, Article no.EJMP.25975 ISSN: 2231-0894, NLM ID: 101583475 SCIENCEDOMAIN international www.sciencedomain.org Ergot Alkaloids: A Review on Therapeutic Applications Niti Sharma 1* , Vinay K. Sharma 1, Hemanth Kumar Manikyam 1 1,2 and Acharya Bal Krishna 1Patanjali Natural Coloroma Pvt. Ltd, Haridwar, Uttarakhand - 249404, India. 2University of Patanjali, Haridwar, Uttarakhand - 249402, India. Authors’ contributions This work was carried out in collaboration between all authors. Authors NS and VKS designed the study, wrote the first draft of the manuscript. Authors ABK and HKM supervised the study. All authors read and approved the final manuscript. Article Information DOI: 10.9734/EJMP/2016/25975 Editor(s): (1) Marcello Iriti, Professor of Plant Biology and Pathology, Department of Agricultural and Environmental Sciences, Milan State University, Italy. Reviewers: (1) Nyoman Kertia, Gadjah Mada University, Indonesia. (2) Robert Perna, Texas Institute of Rehabilitation Research, Houston, TX, USA. (3) Charu Gupta, AIHRS, Amity University, UP, India. Complete Peer review History: http://sciencedomain.org/review-history/14283 Received 28 th March 2016 Accepted 12 th April 2016 Review Article st Published 21 April 2016 ABSTRACT Ergot of Rye is a plant disease caused by the fungus Claviceps purpurea which infects the grains of cereals and grasses but it is being used for ages for its medicinal properties. All the naturally obtained ergot alkaloids contain tetracyclic ergoline ring system, which makes them structurally similar with other neurotransmitters such as noradrenaline, dopamine or serotonin. Due to this structure homology these alkaloids can be used for the treatment of neuro related conditions like migraine, Parkinson’s disease etc.
    [Show full text]
  • Rilutek 109-R-12 Incl Final SPC&PL
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT RILUTEK 50 mg, film-coated tablet. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains riluzole 50 mg For excipients, see 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet The tablets are capsule-shaped, white and engraved with “RPR 202” on one side. 4. CLINICAL PARTICULARS 4.1. Therapeutic indications Riluzole is indicated to extend life or the time to mechanical ventilation for patients with amyotrophic lateral sclerosis (ALS). Clinical trials have demonstrated that RILUTEK extends survival for patients with ALS (See 5.1 Pharmacodynamics properties). Survival was defined as patients who were alive, not intubated for mechanical ventilation and tracheotomy-free. There is no evidence that riluzole exerts a therapeutic effect on motor function, lung function, fasciculations, muscle strength and motor symptoms. Riluzole has not been shown to be effective in the late stages of ALS. Safety and efficacy of riluzole has only been studied in ALS. Therefore, riluzole should not be used in patients with any other form of motor neurone disease. 4.2. Posology and method of administration Treatment with riluzole should only be initiated by specialist physicians with experience in the management of motor neurone diseases. The recommended daily dose in adults or elderly is 100 mg (50 mg every 12 hours). No significant increased benefit can be expected from higher daily doses. Special populations: Children: RILUTEK is not recommended for use in children, as the safety and effectiveness of riluzole in any neurodegenerative diseases occurring in children or adolescents have not been established (see 4.4.
    [Show full text]
  • Data Sheet 1 Rilutek 50Mg Film Coated Tablets
    New Zealand Data Sheet Rilutek - riluzole DATA SHEET 1 RILUTEK 50MG FILM COATED TABLETS Rilutek 50mg film coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film coated tablet contains 50 mg of riluzole, a benzothiazole. For full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM RILUTEK 50 mg riluzole film coated tablets: white, capsule shaped, engraved with the text ‘RPR 202’. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Riluzole is indicated for the treatment of patients with amyotrophic lateral sclerosis (ALS). 4.2 DOSE AND METHOD OF ADMINISTRATION Dose The recommended daily dose in adults or elderly is 100 mg (50 mg every 12 hours). No significant increase in benefit can be expected from higher daily doses. Due to the reduction in absorption observed when administered with high fat meals, Rilutek should not be taken with a fat containing meal. Patients with Impaired Renal Function See section 4.4. rilutek-ccdsv6-dsv6-31oct19 Page 1 New Zealand Data Sheet Rilutek - riluzole Patients with Impaired Hepatic Function See sections 4.3, 4.4 and 5.2. Elderly Based on pharmacokinetic data, there are no special instructions for the use of RILUTEK in this population. Paediatric population RILUTEK is not recommended for use in paediatric population. Method of administration Oral use. 4.3 CONTRAINDICATIONS • Hypersensitivity to riluzole or any of the tablet components listed in Section 6.1. • Patients who have a hepatic disease or hepatic impairment (baseline transaminases greater than 3 times the upper limit of normal). • Patients who are pregnant or lactating. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Liver impairment Riluzole is contraindicated in patients with hepatic disease or hepatic impairment (baseline transaminases greater than 3 times the upper limit of normal).
    [Show full text]